Can-Fite BioPharma (CANF) AI Stock Analysis

• Market Cap: $14.12M
• Dividend Yield: N/A
• Average Volume (3M): 155.97K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.00
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 5
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.14
• Shares Outstanding: 15,772,915
• 10 Day Avg. Volume: 194,339
• 30 Day Avg. Volume: 155,975
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.39
• Enterprise Value/Revenue: 8.27
• Enterprise Value/Gross Profit: 8.27
• Enterprise Value/Ebitda: -0.69
• 1Y Price Target: $0.50
• Price Target Upside: -18.03% Downside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 0

• Rating: 40 Underperform
• Price Target: $0.50 ▼(-18.03% Downside)

The overall stock score reflects significant financial challenges and bearish technical indicators. The company's persistent financial losses and reliance on external financing are major concerns, compounded by negative technical signals. The absence of profitability metrics further underscores the risks associated with this stock.

Can-Fite BioPharma Business Overview & Revenue Model

Company Description

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

How the Company Makes Money

Can-Fite BioPharma generates revenue primarily through a combination of clinical trial funding, strategic partnerships, and potential licensing agreements. The company secures funding for its research and development through grants, collaborations with research institutions, and strategic partnerships with larger pharmaceutical companies, which may include milestone payments and royalties on future sales if products are commercialized. Additionally, Can-Fite has the potential to earn revenue from licensing its drug candidates to partners who wish to develop or market these therapies in specific regions, providing a financial incentive to continue advancing its product pipeline.

Can-Fite BioPharma Financial Statement Overview

Summary

Can-Fite BioPharma is facing significant financial challenges with declining revenues, persistent losses, and reliance on external financing. The income statement shows negative profitability margins and decreasing equity, while the cash flow statement indicates consistent negative free cash flow. Improvements in operational efficiency and revenue growth are crucial to strengthening the company's financial position.

Income Statement

Can-Fite BioPharma's income statement reveals significant challenges, with consistent negative EBIT and net income over the years, indicating ongoing operational inefficiencies. The company has experienced declining revenue, with a revenue decrease of approximately 9.3% from 2023 to 2024. Margins are negative, with a net profit margin of -1169% in 2024, highlighting profitability issues. Despite these challenges, the gross profit margin remains positive due to relatively low cost of goods sold.

Balance Sheet

The balance sheet shows a mixed picture. Can-Fite BioPharma maintains a low level of debt, with a debt-to-equity ratio of 0.019 in 2024, suggesting limited leverage risk. However, the stockholder's equity has been decreasing, indicating potential erosion in financial stability. The equity ratio stands at 59.6%, reflecting a moderate reliance on equity to finance assets. The decreasing equity may pose future risks if the trend continues.

Cash Flow

Cash flow analysis indicates consistent negative free cash flow, which is a concern for sustainability. However, the free cash flow has improved by 9.5% from 2023 to 2024. The operating cash flow to net income ratio is negative, indicating that operations are not generating sufficient cash to cover net losses. The company has relied on financing activities to sustain operations, as seen with substantial financing cash flow in recent years.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	674.00K	743.00K	810.00K	853.00K	763.00K
Gross Profit	674.00K	743.00K	810.00K	853.00K	763.00K
EBITDA	-8.12M	-8.18M	-10.08M	-12.83M	-14.13M
Net Income	-7.88M	-7.63M	-10.53M	-12.60M	-14.81M
Balance Sheet
Total Assets	9.12M	9.99M	9.28M	20.25M	9.52M
Cash, Cash Equivalents and Short-Term Investments	7.89M	8.92M	7.98M	19.14M	8.34M
Total Debt	104.00K	40.00K	62.00K	124.00K	67.00K
Total Liabilities	3.68M	3.75M	4.81M	5.87M	3.45M
Stockholders Equity	5.44M	6.24M	4.47M	14.38M	6.07M
Cash Flow
Free Cash Flow	-7.64M	-8.44M	-10.81M	-9.87M	-12.09M
Operating Cash Flow	-7.64M	-8.44M	-10.80M	-9.86M	-12.06M
Investing Cash Flow	1.50M	498.00K	9.50M	-14.51M	-26.00K
Financing Cash Flow	6.71M	9.14M	0.00	20.46M	17.68M

Can-Fite BioPharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.61
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CANF, the sentiment is Negative. The current price of 0.61 is below the 20-day moving average (MA) of 0.65, below the 50-day MA of 0.71, and below the 200-day MA of 1.20, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 28.35 is Positive, neither overbought nor oversold. The STOCH value of 19.70 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CANF.

Can-Fite BioPharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EQ	56 Neutral	85.68M	-2.47	-42.32%	―	-61.16%	-139.15%
LPCN	52 Neutral	14.96M	-3.18	0.04%	―	-45.78%	47.33%
CING	47 Neutral	20.73M	-0.66	―	―	―	96.32%
CANF	40 Underperform	$14.12M	―	-122.28%	―	―	―
EDSA	35 Underperform	17.38M	-1.84	―	―	―	22.63%
UNBX	31 Underperform	1.03M	-0.04	―	―	―	35.08%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Can-Fite BioPharma Corporate Events

Can-Fite BioPharma Announces Breakthrough in Liver Disease Treatment with Namodenoson

On September 15, 2025, Can-Fite BioPharma announced a significant clinical finding in its compassionate use program for decompensated liver cirrhosis. A patient treated with Namodenoson showed a complete resolution of esophageal varices, a severe complication of advanced liver disease. This outcome, confirmed by endoscopic evaluation, suggests a potential disease-modifying effect of Namodenoson. The drug is currently in Phase III trials for hepatocellular carcinoma and has shown promise in treating other conditions, highlighting its therapeutic potential in a market with limited treatment options.

Can-Fite BioPharma Reports Mid-2025 Financial Results and Drug Development Updates

On August 28, 2025, Can-Fite BioPharma Ltd. announced its financial results for the first half of 2025 and provided updates on its drug development programs. The company released unaudited interim condensed consolidated financial statements as of June 30, 2025. These announcements are significant as they provide insights into the company’s financial health and progress in drug development, potentially impacting its market positioning and stakeholder interests.

Can-Fite BioPharma Achieves Enrollment Milestone in Pancreatic Cancer Trial

On July 30, 2025, Can-Fite BioPharma Ltd. announced that its Phase 2a trial of Namodenoson for pancreatic cancer has achieved over 50% enrollment. The trial is focused on evaluating the safety, clinical activity, and pharmacokinetics of Namodenoson in patients with advanced pancreatic adenocarcinoma. The drug has shown a favorable safety profile and has been granted Orphan Drug Designation by the FDA. This milestone reflects significant interest in Namodenoson as a potential treatment for pancreatic cancer, highlighting Can-Fite’s commitment to advancing therapeutic options for this aggressive disease.

Can-Fite BioPharma Raises $5 Million in Public Offering

On July 28, 2025, Can-Fite BioPharma Ltd. conducted a public offering, raising approximately $5.0 million through the sale of American Depositary Shares (ADSs) and warrants. The net proceeds of $4.19 million, after deducting fees and expenses, will be used for working capital, research and development, and clinical trials. This offering, expected to close on July 29, 2025, is part of the company’s strategy to strengthen its financial position and support its ongoing drug development efforts.

Can-Fite BioPharma Announces $15 Million Public Offering

On July 28, 2025, Can-Fite BioPharma Ltd. announced a public offering expected to raise up to $15 million, with $5 million upfront and an additional $10 million possible from short-term warrants. The offering, involving 8,333,333 American Depositary Shares and warrants, is priced at $0.60 per ADS and is expected to close on July 29, 2025. The proceeds will fund research, clinical trials, and general corporate purposes, potentially impacting the company’s operational capabilities and market positioning.

Can-Fite BioPharma’s Piclidenoson Shows Promise in Vascular Dementia Treatment

On July 28, 2025, Can-Fite BioPharma Ltd. announced a breakthrough study from UCLA demonstrating the efficacy of its drug Piclidenoson in treating vascular dementia. Conducted by Dr. S. Thomas Carmichael, the study showed that Piclidenoson restored tissue integrity and behavioral function in a vascular dementia mouse model. Vascular dementia, the second most common cause of dementia after Alzheimer’s, currently lacks FDA-approved therapies. With an aging population and increasing diagnosis, the global market for vascular dementia is estimated at $6 billion in 2025. Piclidenoson, a selective A3 adenosine receptor agonist, could fulfill a significant unmet need in this market, potentially capturing a large share due to its neuroprotective properties and ability to improve vascular health.

Can-Fite BioPharma’s Shareholders Approve Key Proposals at Annual Meeting

On June 30, 2025, Can-Fite BioPharma Ltd. held its Annual General Meeting of Shareholders, where all six proposals presented were approved by the required majority. These proposals, detailed in a prior notice and proxy statement, reflect the company’s strategic decisions and governance practices, potentially impacting its operational and market positioning.